Oncopeptides has enrolled the first patient into its new real‑world evidence study, Marina, which is being carried out across Germany to evaluate the use of Pepaxti with dexamethasone in adults with relapsed, refractory multiple myeloma.
The company said the study, run by iOMEDICO, will follow 50 patients at around 25 clinical sites. It focuses on individuals who have already received at least three prior lines of therapy, matching the approved European indication for Pepaxti.
According to the company, the study is intended to capture how the treatment performs in everyday healthcare settings and to help close the gap between controlled trials and routine clinical practice. It will examine measures such as Disease Control Rate and Pepaxti’s potential role as a bridging or sequencing option alongside immunotherapies including CAR‑T cells and bispecific antibodies.
Oncopeptides noted that the first enrolment meets its previously communicated timeline for the second quarter of 2026. The study is supported by the SYNERGY platform, which uses what the company described as an agile recruitment model that activates centres ‘just‑in‑time’ once an eligible patient is identified.
Oncopeptides provides financial backing for the project, while iOMEDICO acts as sponsor and coordinator. The company said the findings will add important real‑world data to support engagement with healthcare professionals, prescribers and regulators across Europe.
An Oncopeptides spokesperson said: “The initiation and first enrollment of the study align with the previously communicated timeline for the second quarter of 2026.”
“They added that the study aims to generate data that will ‘further strengthen the European real-world evidence base for Pepaxti, supporting continuous engagement with healthcare providers, clinical prescribers, and regulatory bodies.”
